Cybin (CYBN) announced that it has engaged Thermo Fisher (TMO) to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, the company’s proprietary deuterated psilocin program in Phase 3 development for the adjunctive treatment of Major Depressive Disorder.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment
- Psychedelic: Compass, GH Research, MindMed report quarterly earnings
- Cybin announces USPTO patent in support of CYB003 program
- Cybin Secures New U.S. Patent for CYB003 Program in Major Depressive Disorder
- Cybin CEO to Speak at Milken Institute Global Conference on Medical Breakthroughs